http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic medicines and commercial readiness
-
Biogen (BIIB), Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
-
Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
-
Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
-
Ionis to present at 41st Annual J.P. Morgan Healthcare conference
-
Ionis Pharmaceuticals (IONS) announces EMA accepts Marketing Authorization Application of tofersen to treat rare, genetic form of ALS
-
Ionis announces European Medicines Agency accepts Marketing Authorization Application of tofersen to treat rare, genetic form of ALS
-
Ionis Pharmaceuticals (IONS) Partners with Metagenomi to Add Gene Editing
-
Ionis partners with Metagenomi to add gene editing to its broad technology platform
-
Ionis (IONS) Reports Positive Phase 2 Data from Open Label Extension Study of donidalorsen
-
Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting
-
Ionis to present at upcoming investor conferences
-
Ionis reports third quarter financial results
-
Ionis Pharmaceuticals (IONS) Reports Positive Data from GSK's Phase 2b Study of bepirovirsen
-
Ionis announces positive data from GSK's Phase 2b clinical study of bepirovirsen
-
Ionis Pharmaceuticals (IONS) Reports Positive Phase 2 data in Patients with IgA Nephropathy
-
Ionis presents positive Phase 2 data in patients with IgA Nephropathy at American Society of Nephrology's Kidney Week 2022
-
Ionis Pharmaceuticals (IONS) Reports Positive Phase 2 Results of fesomersen
-
Ionis announces positive results from fesomersen development program
-
Ionis to hold third quarter 2022 financial results webcast
-
Ionis announces plan for new manufacturing facility in Oceanside, Calif.
-
Ionis provides update on development program evaluating PCSK9 antisense medicine for the treatment of hypercholesterolemia
-
Invitae’s Real-World Ciitizen Data Utilized in Praxis Precision Medicines’ PRAX-222 IND Filing
-
Invitae's Real-World Ciitizen Data Utilized in Praxis Precision Medicines' PRAX-222 IND Filing
-
Praxis Precision Medicines (PRAX) Provides Updates on Clinical Stage Pediatric Epilepsy Programs
-
Ionis Pharmaceuticals (IONS) Presented Positive Phase 3 NEURO-TTRansform Study Results at ISA
-
Ionis presents positive results from Phase 3 NEURO-TTRansform study at International Symposium on Amyloidosis
-
Ionis to present at upcoming investor conferences
-
Ionis reports second quarter financial results and recent business achievements
-
Ionis Pharmaceuticals (IONS) Reports Positive Topline Results from Phase 2b Study of fesomersen
-
Ionis announces positive topline results from Phase 2b clinical study of fesomersen, a potential novel anti-thrombotic treatment
-
Ionis to hold second quarter 2022 financial results webcast
-
Ionis Pharmaceuticals (IONS) announces that FDA accepts New Drug Application and grants Priority Review of tofersen for a rare, genetic form of ALS
-
Ionis announces that FDA accepts New Drug Application and grants Priority Review of tofersen for a rare, genetic form of ALS
-
Ionis announces enrollment completion of Phase 3 Lp(a) HORIZON cardiovascular outcomes study of pelacarsen
-
Ionis to participate in virtual fireside chat at H.C. Wainwright 1st Annual Hereditary Angioedema Conference
-
Ionis Pharmaceuticals (IONS) partner licenses rare kidney disease treatment and will advance into Phase 3 clinical study
-
Ionis partner licenses rare kidney disease treatment and will advance into Phase 3 clinical study
-
Ionis announces presentation of positive Phase 2b data for chronic hepatitis B treatment at the EASL International Liver Congress™
-
Ionis announces eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)
-
Biogen (BIIB) Announces New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treated With Gene Therapy and Suggest Further Potential of Using SPINRAZA
-
New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treated With Gene Therapy and Suggest Further Potential of Using SPINRAZA® (nusinersen)
-
Ionis Pharmaceuticals (IONS) treatment for Angelman syndrome receives orphan drug and rare pediatric disease designations from U.S. FDA
-
Ionis treatment for Angelman syndrome receives orphan drug and rare pediatric disease designations from U.S. FDA
-
Ionis partner Biogen announces that results from Phase 3 VALOR study and open-label extension of tofersen showed clinical benefit in SOD1-ALS patients
-
Ionis to present at RBC Capital Markets Global Healthcare Conference
-
Ionis reports first quarter financial results and recent business achievements
-
Ionis to host 2022 virtual Annual Meeting of Stockholders
-
Ionis to hold first quarter 2022 financial results webcast
-
Ionis Pharmaceuticals (IONS) Reports Positive Data for ETESIAN Phase 2b Study
